Psychedelic medicine is approaching a turning point. The U.S. needs the right infrastructure to be ready

On September 14, the FDA set aside four hours and invited more than 80 speakers to consider how psychedelic therapies might work in regulated settings.

The discussion reflected growing interest from regulators, physicians, patients, and veterans’ organizations in how these potential treatments may offer relief to those living with mental illness.

But it also revealed a gap beyond rescheduling or reclassification: the infrastructure needed to deliver these therapies safely and at scale.

It’s clear there is a significant patient need.

More than 62 million American adults live with mental illness, and tens of millions have few, if any, treatments that work.

Nearly one in three patients treated for major depressive disorder sees no meaningful relief from medication, and first-line post-traumatic stress disorder (PTSD) treatments carry an average nonresponse rate of 40%.

Psychedelic therapies could provide one of the solutions to this crisis.

Findings from a 2022 trial published in the New England Journal of Medicine showed a single 25 mg dose of psilocybin, with psychological support, significantly reduced depressive symptoms in treatment-resistant patients.

Similarly, Oregon Health & Science University published findings from the largest real-world U.S. study of psilocybin, including 346 people and 24 licensed service centers, with participants reporting reduced symptoms of depression, anxiety, and PTSD.

Nearly two-thirds ranked the session among the most meaningful experiences of their lives.

Today’s psychedelics bear little resemblance to their 1970s counterparts.

These medicines undergo rigorous clinical trials and licensed manufacturing processes to preserve safety, chain of custody, and their therapeutic effect.

The clinical foundation has been established, and now the U.S. needs the operational foundation to act on it.

For these psychedelic therapies to reach patients and make an impact, more is involved than rescheduling and FDA approval.